Nov 3, 2022 · Renin–angiotensin system (RAS) inhibitors — including angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) — slow the progression of mild or moderate...

Sep 13, 2022 · The renin–angiotensin–aldosterone system (RAAS) is a critical regulator of blood volume and systemic vascular resistance on a long-term basis. The baroreceptor reflex, on the other hand, responds in a short-term manner to decreased blood pressure.

3.2. RAAS Activation in CKD. CKD is a pathological condition associated with an unexplained decrease in the glomerular filtration rate (GFR) (<0.06 L/min) for more than three months.

The acknowledged importance of the intrarenal RAAS in the pathogenesis of hypertension and chronic kidney disease (CKD) and the clinical availability of aliskiren, a direct renin inhibitor (DRI), have stimulated renewed interest in therapeutic options to modulate the function of the RAAS.

Renin-angiotensin-aldosterone system inhibitors (RAASi) have been repeatedly demonstrated to significantly slow progression of CKD in randomized controlled trials conducted in adults (1, 2). The mechanisms by which RAASi slow progression of CKD include the reduction of proteinuria and optimized BP control (3).

Mar 25, 2023 · Renin-angiotensin system (RAS) inhibitors have been the preferred antihypertensive agents in the setting of chronic kidney disease (CKD) since the 1990s.

Aug 8, 2017 · Overactivity of RAAS contributes to the pathogenesis of a variety of clinical conditions including progress of chronic kidney disease (CKD). This review summarizes the use of RAAS inhibitors as dual therapy or monotherapy in different stages of kidney disease.

Aug 22, 2023 · The Renin-Angiotensin-Aldosterone System (RAAS) is a hormone system within the body that is essential for the regulation of blood pressure and fluid balance. The system is mainly comprised of the three hormones renin , angiotensin II, and aldosterone .

ACE inhibitors and angiotensin II receptor antagonists can be used in combination to maximize RAAS inhibition and more effectively reduce proteinuria and GFR decline in diabetic and nondiabetic renal disease.

Two newer potassium binders, patiromer and sodium zirconium cyclosilicate (ZS-9), have been shown to effectively and safely reduce serum potassium levels and maintain long-term normokalemia in CKD patients receiving background therapy with RAAS inhibitors.